Synergistic effect of decreased opioid activity and sleep deprivation on head-twitch response in mice

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 1, 2010, Pages 48-51

  Ionov, Ilya D ^a  

^a CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

Author keywords

5 HT(2A) receptor; Head twitches; Opioidergic stimulation; Schizophrenia; Sleep deprivation

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; ENKEPHALIN; METHIONINE; NALOXONE; OPIATE RECEPTOR; SEROTONIN 2A RECEPTOR; VOLINANSERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEAD TWITCH; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PSYCHOSIS; RECEPTOR BLOCKING; SCHIZOPHRENIA; SLEEP DEPRIVATION; TIME;

ANIMALS; FLUOROBENZENES; HEAD MOVEMENTS; MALE; MICE; MICE, INBRED C57BL; NARCOTIC ANTAGONISTS; PIPERIDINES; RANDOM ALLOCATION; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, OPIOID; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SLEEP DEPRIVATION;

ANIMALIA; MUS;

EID: 77953320993     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.04.005     Document Type: Article

References (39)

1. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997, 36:589-599.
2. Andersen M.L., Martins P.J., D'Almeida V., Bignotto M., Tufik S. Endocrinological and catecholaminergic alterations during sleep deprivation and recovery in male rats. J Sleep Res 2005, 14:83-90.
3. Bhargava H.N. Effects of methionine-enkephalin and morphine on spontaneous locomotor activity, antagonism by naloxone. Pharmacol Biochem Behav 1978, 9:167-171.
4. Bloom F., Segal D., Ling N., Guillemin R. Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. Science 1976, 194:630-632.
5. Carr AA, Kane JM, Hay DA. (+)-α-(2,3-dimethoxyphenyl)-1-[ 2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. US Patent 5,134,149, US Cl.514/317, 1992.
6. Carter O.L., Hasler F., Pettigrew J.D., Wallis G.M., Liu G.B., Vollenweider F.X. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) 2007, 195:415-424.
7. Chouinard S., Poulin J., Stip E., Godbout R. Sleep in untreated patients with schizophrenia, a meta-analysis. Schizophr Bull 2004, 30:957-967.
8. Fantegrossi W.E., Reissig C.J., Katz E.B., Yarosh H.L., Rice K.C., Winter J.C. Hallucinogen-like effects of N, N-dipropyltryptamine (DPT), possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav 2008, 88:358-365.
9. Fishman J., Hahn E.F., Norton B.I. Comparative in vivo distribution of opiate agonists and antagonists by means of double isotope techniques. Life Sci 1975, 17:1119-1125.
10. Ganguli R., Reynolds C.F., Kupfer D.J. Electroencephalographic sleep in young, never-medicated schizophrenics. A comparison with delusional and nondelusional depressives and with healthy controls. Arch Gen Psychiatry 1987, 44:36-44.
11. Geyer M.A., Vollenweider F.X. Serotonin research, contributions to understanding psychoses. Trends Pharmacol Sci 2008, 29:445-453.
12. Gorzalka B.B., Brotto L.A., Hong J.J. Corticosterone regulation of 5-HT2A receptor-mediated behaviors: attenuation by melatonin. Physiol Behav 1999, 67:439-442.
13. Guaza C., Borrell J. The Met-enkephalin analog d-Ala2-Met-enkephalinamide decreases the adrenocortical response to ACTH in dispersed rat adrenal cells. Peptides 1984, 5:895-897.
14. Heal D.J., Philpot J., O'Shaughnessy K.M., Davies C.L. The influence of central noradrenergic function on 5-HT2-mediated head-twitch responses in mice, possible implications for the actions of antidepressant drugs. Psychopharmacology (Berl) 1986, 89:414-420.
15. Jennings K.A., Sheward W.J., Harmar A.J., Sharp T. Evidence that genetic variation in 5-HT transporter expression is linked to changes in 5-HT2A receptor function. Neuropharmacology 2008, 54:776-783.
16. Keeler M.H. Similarity of schizophrenia and the psilocybin syndrome as determined by objective methods. Int J Neuropsychiatry 1965, 1:630-634.
17. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100, 907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996, 277:968-981.
18. Kleinman J.E., Hong J., Iadarola M., Govoni S., Gillin C.J. Neuropeptides in human brain-postmortem studies. Prog Neuropsychopharmacol Biol Psychiatry 1985, 9:91-95.
19. Kornhuber J., Weller M. Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenien [in German]. Nervenarzt 1994, 65:741-754.
20. Kornhuber J., Wiltfang J., Bleich S. The etiopathogenesis of schizophrenias. Pharmacopsychiatry 2004, 37(Suppl 2):S103-S112.
21. Lord J.A., Waterfield A.A., Hughes J., Kosterlitz H.W. Endogenous opioid peptides, multiple agonists and receptors. Nature 1977, 267:495-499.
22. Marek G.J., Aghajanian G.K. 5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells, suppression by mu-opiate receptor activation. Neuroscience 1998, 86:485-497.
23. Michael-Titus A., Dourmap N., Caline H., Costentin J., Schwartz J.C. Role of endogenous enkephalins in locomotion and nociception studied with peptidase inhibitors in two inbred strains of mice (C57BL/6J and DBA/2J). Neuropharmacology 1989, 28:117-122.
24. Monti J.M., Jantos H. Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. Eur J Pharmacol 2006, 553:163-170.
25. Odio M., Brodish A. Central but not peripheral opiate receptor blockade prolonged pituitary-adrenal responses to stress. Pharmacol Biochem Behav 1990, 35:963-969.
26. Peñalva R.G., Lancel M., Flachskamm C., Reul J.M., Holsboer F., Linthorst A.C. Effect of sleep and sleep deprivation on serotonergic neurotransmission in the hippocampus: a combined in vivo microdialysis/EEG study in rats. Eur J Neurosci 2003, 17:1896-1906.
27. Rechtschaffen A., Gilliland M.A., Bergmann B.M., Winter J.B. Physiological correlates of prolonged sleep deprivation in rats. Science 1983, 221:182-184.
28. Renegar K.B., Floyd R., Krueger J.M. Effect of sleep deprivation on serum influenza-specific IgG. Sleep 1998, 21:19-24.
29. Rueter L.E., Tecott L.H., Blier P. In vivo electrophysiological examination of 5-HT2 responses in 5-HT2C receptor mutant mice. Naunyn Schmiedebergs Arch Pharmacol 2000, 361:484-491.
30. Schöpf J. Biogene Amine und Schizophrenie [in German]. Schweiz Med Wochenschr 1975, 105:1201-1209.
31. Schreiber R., Brocco M., Audinot V., Gobert A., Veiga S., Millan M.J. (1-(2, 5-Dimethoxy-4-iodophenyl)-2-aminopropane)-induced head twitches in the rat are mediated by 5-hydroxytryptamine (5-HT2A) receptors, modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 1995, 273:101-112.
32. Sperner-Unterweger B. Biologische Hypothesen zur Schizophrenie, Mögliche Einflüsse von Immunologie und Endokrinologie [in German]. Fortschr Neurol Psychiatr 2005, 73(Suppl 1):S38-S43.
33. Tandon R., Shipley J.E., Taylor S., Greden J.F., Eiser A., DeQuardo J., et al. Electroencephalographic sleep abnormalities in schizophrenia. Relationship to positive/negative symptoms and prior neuroleptic treatment. Arch Gen Psychiatry 1992, 49:185-194.
34. Vickers S.P., Easton N., Malcolm C.S., Allen N.H., Porter R.H., Bickerdike M.J., et al. Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists. Pharmacol Biochem Behav 2001, 69:643-652.
35. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Bäbler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998, 9:3897-3902.
36. Wen H.L., Lo C.W., Ho W.K. Met-enkephalin level in the cerebrospinal fluid of schizophrenic patients. Clin Chim Acta 1983, 128:367-371.
37. Willins D.L., Meltzer H.Y. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 1997, 282:699-706.
38. Winter J.C., Kieres A.K., Zimmerman M.D., Reissig C.J., Eckler J.R., Ullrich T., et al. The stimulus properties of LSD in C57BL/6 mice. Pharmacol Biochem Behav 2005, 81:830-837.
39. Yang C., Winkelman J.W. Clinical significance of sleep EEG abnormalities in chronic schizophrenia. Schizophr Res 2006, 82:251-260.